A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis

By sjmartinez • March 4, 2025

Mozas P, Ould Ammar R, Chartier L, Nastoupil L, Bachy E, Bezsera SM, Barnes J, Bijou F, Goy A, Zerazhi H, Cartron G, Ojeda-Uribe M, Choquet S, Joly B, Cheminant M, Martín García-Sancho A, Eradat H, Gressin R, Abrisqueta P, Parcelier A, Rodríguez Salazar MJ, Bonnet C, Johnson NA, López-Guillermo A, Morschhauser F. A low lymphocyte-to-monocyte ratio is independently associated with early relapse (POD24) in high tumour burden follicular lymphoma: A RELEVANCE subanalysis. Br J Haematol. 2025 Mar 3. doi: 10.1111/bjh.20038. Epub ahead of print. PMID: 40031898.

Tags: chemoimmunotherapy, follicular lymphoma, Hematology/Oncology, lymphocyte‐to‐monocyte ratio, prognosis, Publications, rituximab–lenalidomide, survival

A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design

Ji J, Crespi CM, Yee L, Zekster YA, Al-Saleem A, Petersen L, Lee C, Son N, Smith C, Evans T, Tchkonia T, Kirkland JL, Kuchel[...]

First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies

Razak A, Mahipal A, Diamond JR, Ribas A, Berlin JD, Azmi AS, Mark T, Walker CJ, Chai Y, Kashyap T, Gudi G, Naing A. First-in-Human[...]

Surgical Outcomes of Prepectoral Two-Stage Breast Reconstruction in Patients Treated with Pembrolizumab or CDK4/6 Inhibitors

Ibrahim Y, Alnaseri T, Gupta N, Hall A, Carter M, Kwan L, Demirjian M, McCann KE, Teshome M, Delong MR. Surgical Outcomes of Prepectoral Two-Stage[...]